KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Cash from Investing Activities (2016 - 2025)

Bio-Rad Laboratories (BIO) has disclosed Cash from Investing Activities for 17 consecutive years, with -$34.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Investing Activities fell 12.13% to -$34.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$189.7 million, a 18.41% decrease, with the full-year FY2025 number at -$189.7 million, down 18.41% from a year prior.
  • Cash from Investing Activities was -$34.2 million for Q4 2025 at Bio-Rad Laboratories, up from -$43.0 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $72.2 million in Q4 2023 to a low of -$916.1 million in Q1 2022.
  • A 5-year average of -$116.7 million and a median of -$52.0 million in 2021 define the central range for Cash from Investing Activities.
  • Peak YoY movement for Cash from Investing Activities: plummeted 1795.71% in 2022, then surged 223.28% in 2023.
  • Bio-Rad Laboratories' Cash from Investing Activities stood at -$567.4 million in 2021, then soared by 89.68% to -$58.6 million in 2022, then soared by 223.28% to $72.2 million in 2023, then plummeted by 142.25% to -$30.5 million in 2024, then decreased by 12.13% to -$34.2 million in 2025.
  • Per Business Quant, the three most recent readings for BIO's Cash from Investing Activities are -$34.2 million (Q4 2025), -$43.0 million (Q3 2025), and -$115.4 million (Q2 2025).